Is There an Independent Role of TERT and NF1 in High Grade Gliomas?
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
10
07
2019
revised:
25
10
2019
accepted:
29
10
2019
pubmed:
1
1
2020
medline:
1
1
2020
entrez:
1
1
2020
Statut:
ppublish
Résumé
High grade glioma molecular profiling is of particular interest in neurooncology. The role of telomerase reverse transcriptase (TERT) varies dependent upon other molecular parameters. We explored the role of TERT in 101 high-grade gliomas. A total of 101 patients (pts) with grade III-IV gliomas treated with standard of care and informative tumor genotypes were included in the present study. Of 55 genes targeted with the next-generation sequencing panel, mutations (muts) were found in 37; these were included in the analysis. TERT mut were tested with Sanger sequencing. MGMT promoter methylation status was determined by methylation specific PCR. 270 mut were detected in 92/101 tumors (91.1%). TERT was the most frequently mutated gene (74.3%). IDH1/2 mut were mutually exclusive with mut in the neurofibromin 1 (NF1) gene. Mutated TERT was associated with wild-type (wt) IDH1/2 (p = 0.025). The 12-month overall survival (OS) rate was 74.3% (median OS: 22 months). Pts with TERT and NF1 wt had a median OS of 40.8 months, while among pts with NF1 wt/TERT mutant, the median OS was 18.5 months. NF1 and TERT mut univariately conferred shorter OS (HR = 3.19; p = 0.004 and HR = 2.28; p = 0.002). Upon multivariate analysis, mutated TERT showed marginal unfavorable prognostic significance for OS (p = 0.049), while NF1 lost its unfavorable significance (p = 0.151). TERT is herein proven to confer poor prognosis in high grade gliomas, independent of IDH and MGMT. NF1 seems to also confer poor prognosis although our small numbers do not allow for firm conclusions.
Sections du résumé
BACKGROUND
BACKGROUND
High grade glioma molecular profiling is of particular interest in neurooncology. The role of telomerase reverse transcriptase (TERT) varies dependent upon other molecular parameters. We explored the role of TERT in 101 high-grade gliomas.
METHODS
METHODS
A total of 101 patients (pts) with grade III-IV gliomas treated with standard of care and informative tumor genotypes were included in the present study. Of 55 genes targeted with the next-generation sequencing panel, mutations (muts) were found in 37; these were included in the analysis. TERT mut were tested with Sanger sequencing. MGMT promoter methylation status was determined by methylation specific PCR.
RESULTS
RESULTS
270 mut were detected in 92/101 tumors (91.1%). TERT was the most frequently mutated gene (74.3%). IDH1/2 mut were mutually exclusive with mut in the neurofibromin 1 (NF1) gene. Mutated TERT was associated with wild-type (wt) IDH1/2 (p = 0.025). The 12-month overall survival (OS) rate was 74.3% (median OS: 22 months). Pts with TERT and NF1 wt had a median OS of 40.8 months, while among pts with NF1 wt/TERT mutant, the median OS was 18.5 months. NF1 and TERT mut univariately conferred shorter OS (HR = 3.19; p = 0.004 and HR = 2.28; p = 0.002). Upon multivariate analysis, mutated TERT showed marginal unfavorable prognostic significance for OS (p = 0.049), while NF1 lost its unfavorable significance (p = 0.151).
CONCLUSIONS
CONCLUSIONS
TERT is herein proven to confer poor prognosis in high grade gliomas, independent of IDH and MGMT. NF1 seems to also confer poor prognosis although our small numbers do not allow for firm conclusions.
Identifiants
pubmed: 31891871
pii: S1936-5233(19)30350-X
doi: 10.1016/j.tranon.2019.10.016
pmc: PMC6940679
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
346-354Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Nat Genet. 2013 Oct;45(10):1141-9
pubmed: 23917401
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Pathol Res Pract. 2018 Jun;214(6):881-888
pubmed: 29650441
Cancer Cell. 2005 Aug;8(2):119-30
pubmed: 16098465
Acta Neuropathol Commun. 2017 Aug 29;5(1):62
pubmed: 28851427
Transl Oncol. 2012 Oct;5(5):393-7
pubmed: 23066447
Brain Tumor Pathol. 2018 Jan;35(1):10-18
pubmed: 29138945
Neuro Oncol. 2016 Aug;18(8):1099-108
pubmed: 26957363
Hum Pathol. 2015 Sep;46(9):1323-30
pubmed: 26190195
Acta Neuropathol. 2013 Sep;126(3):443-51
pubmed: 23904111
Brain Pathol. 2017 Mar;27(2):146-159
pubmed: 26919320
Trends Genet. 2013 Jun;29(6):358-66
pubmed: 23453263
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
J Cell Physiol. 2018 Jan;233(1):378-386
pubmed: 28266716
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
Sci Transl Med. 2015 Apr 15;7(283):283ra54
pubmed: 25877892
Oncol Lett. 2017 Dec;14(6):8213-8219
pubmed: 29344264
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150
pubmed: 28815663
Crit Rev Oncol Hematol. 2017 Dec;120:1-9
pubmed: 29198322
Cancer Cell. 2009 Jul 7;16(1):44-54
pubmed: 19573811
Acta Neuropathol Commun. 2016 Aug 08;4(1):79
pubmed: 27503138
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cell. 1990 Jul 13;62(1):193-201
pubmed: 2114220
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Hum Genomics. 2017 Jun 21;11(1):13
pubmed: 28637487
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Neuro Oncol. 2017 Mar 1;19(3):394-404
pubmed: 27571882
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237